AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34037955
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of aerobic exercise plus conventional treatment vs. conventional treatment alone
Trial: 35401732
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (in addition to escitalopram oxalate)
Trial: 34077745
Drug: Topical betamethasone
RxNorm normalized name: betamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betamethasone eye drops
Trial: 34551229
Drug: Control (investigator's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (investigator's choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine)
Trial: 35799239
Drug: Lactulose monotherapy
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose monotherapy
Trial: 35799239
Drug: S. boulardii
RxNorm normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. boulardii monotherapy
Trial: 35489037
Drug: 0.3% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% chlorhexidine gluconate vaginal preparation
Trial: 34022790
Drug: Three antihypertensive
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three antihypertensive regimens for 6 months
Trial: 33559212
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (traditional dorsogluteal injection)
Trial: 35902298
Drug: Carryover voice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carryover voice therapy using carryover strategies
Trial: 35902298
Drug: Traditional voice
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional voice therapy with no emphasis on generalizing process
Trial: 35902298
Drug: Carryover voice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carryover voice therapy
Trial: 35902298
Drug: Controls (eight-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controls (eight-week non-therapy period)
Trial: 32751170
Drug: 28 g
RxNorm normalized name: SM Syringe 28 g, 0.5cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 g of rapeseed protein isolate
Trial: 32105268
Drug: Recognan (citicoline),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recognan (citicoline), 100 mg in 1 ml, taken orally for 30 days (daily dosage of 0.5 g).
Trial: 32105268
Drug: Comparison group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison group (no medication).
Trial: 35990057
Drug: taVNS combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: taVNS combined with electroacupuncture (8 weeks, 3 sessions per week for taVNS; 8 weeks, twice per day for electroacupuncture)
Trial: 35990057
Drug: citalopram (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: citalopram (8 weeks, 40 mg/day)
Trial: 33861432
Drug: Curcumin supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin supplement (500 mg daily for 12 weeks)
Trial: 32474935
Drug: Platform-switching (PS)
RxNorm normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platform-switching (PS) implants
Trial: 32474935
Drug: Platform-matching (PM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platform-matching (PM) implants
Trial: 38691823
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) and radiation therapy (RT)
Trial: 32540986
Drug: DOSE HPV
RxNorm normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOSE HPV intervention (7-session program including provider education, communication training, data feedback, and tailored systems change)
Trial: 32540986
Drug: DOSE HPV
RxNorm normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOSE HPV intervention
Trial: 38982653
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose regimen
Trial: 32086901
Drug: Nasal spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray allergen blocker combined with azelastine hydrochloride nasal spray
Trial: 32086901
Drug: Azelastine hydrochloride
RxNorm normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azelastine hydrochloride nasal spray
Trial: 33621541
Drug: ticagrelor plus
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ticagrelor plus aspirin (DAPT)
Trial: 36327527
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) Q3W for four cycles with once-daily cabozantinib (40 mg), then nivolumab (240 mg) Q2W plus once-daily cabozantinib (40 mg)
Trial: 35597972
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy/Motivational Interviewing (CBT/MI) intervention, administered in six sessions over 3 months.
Trial: 32706937
Drug: Ribociclib 600-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib 600-mg tablet
Trial: 32706937
Drug: Ribociclib 600-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib 600-mg capsule
Trial: 32706937
Drug: Ribociclib intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib intravenous infusion 150 mg
Trial: 32706937
Drug: Ribociclib oral
RxNorm normalized name: ribociclib Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib oral administration
Trial: 32706937
Drug: Ribociclib 600-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib 600-mg tablet and capsule
Trial: 33287685
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT), 4 sessions of 1 hour
Trial: 34134828
Drug: Pill placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill placebo augmented ERP
Trial: 34529768
Drug: ATRA chemotherapy
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATRA chemotherapy
Trial: 36152268
Drug: anti-HBc level
RxNorm normalized name: Aminosyn-HBC 7 %, Sulfite-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-HBc level <325 IU/ml
Trial: 36152268
Drug: anti-HBc level
RxNorm normalized name: Aminosyn-HBC 7 %, Sulfite-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-HBc level ≥325 IU/ml
Trial: 36152268
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of anti-HBc <325 IU/ml with HBsAg >3008 IU/ml
Trial: 36152268
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of anti-HBc <325 IU/ml with HBcrAg ≥1790 U/ml
Trial: 36258168
Drug: Padres Preparados,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Padres Preparados, Jóvenes Saludables program (8 weekly sessions of 2.5 hours each)
Trial: 34019540
Drug: Usual medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual medicine access (n = 391)
Trial: 36129708
Drug: Nonpharmacologic interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonpharmacologic interventions including earplugs, eye mask, aromatherapy, and postponed morning medication and vital sign measurement rounds.
Trial: 36129708
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group with postponed vital sign checks and medication rounds.
Trial: 33177349
Drug: Infliximab (IFX)
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab (IFX) combo therapy
Trial: 34018375
Drug: MRI after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI after vaginal filling with ultrasound gel
Trial: 32176792
Drug: Linezolid administered
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid administered intravenously at a standard dose of 600 mg every 12 hours with CVVH
Trial: 32176792
Drug: Linezolid administered
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid administered intravenously at a standard dose of 600 mg every 12 hours with EDH
Trial: 32176792
Drug: Standard 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 600 mg intravenous administration every 12 hours
Trial: 33443915
Drug: Twice‐daily application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice‐daily application of a commercially available skin and body lotion to the arms and legs of participants
Trial: 34062589
Drug: Team-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Team-based treatment (blended collaborative care) in secondary prevention
Trial: 33744043
Drug: BUZZY® vibratory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUZZY® vibratory stimulation tool (switched on before injection)
Trial: 33264556
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no trial drug)
Trial: 32950590
Drug: Budesonide (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (9 mg/day)
Trial: 34343292
Drug: 60 µg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 µg/day of D3 for 8 weeks
Trial: 34343292
Drug: 20 µg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 µg/day of 25(OH)D3 for 8 weeks
Trial: 35331677
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate (4 g of magnesium sulphate heptahydrate, 8 mmol magnesium ions)
Trial: 33364042
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin A plus E supplementation (AE group, N = 36)
Trial: 33364042
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin A plus E with zinc (AEZ group, N = 35)
Trial: 33364042
Drug: No supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplements (control group, N = 27)
Trial: 33544819
Drug: 30 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg/day valproic acid orally for 14 days
Trial: 32859487
Drug: Bilateral pectointercostal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral pectointercostal fascial block using ropivacaine injection 0.25%
Trial: 34516497
Drug: Xianling Gubao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xianling Gubao capsule + glucosamine hydrochloride capsule simulation agent treatment
Trial: 34516497
Drug: Glucosamine hydrochloride
RxNorm normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine hydrochloride capsule + Xianling Gubao capsule simulation agent treatment
Trial: 36570810
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine (0.5 mg/kg)
Trial: 32305653
Drug: Mechanical debridement
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical debridement with adjuvant antimicrobial photodynamic therapy (aPDT)
Trial: 35241006
Drug: Blister packaged
RxNorm normalized name: Blister Armour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blister packaged IFA pills
Trial: 35241006
Drug: Loose packaged
RxNorm normalized name: loose wheat smut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loose packaged IFA pills
Trial: 34019802
Drug: TAK-426 2
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-426 2 μg
Trial: 34019802
Drug: TAK-426 5
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-426 5 μg
Trial: 34019802
Drug: TAK-426 10
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-426 10 μg
Trial: 34019802
Drug: TAK-426 10
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-426 10 μg vs 2 μg
Trial: 34019802
Drug: TAK-426 10
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-426 10 μg vs 5 μg
Trial: 35811050
Drug: CBD-rich oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD-rich oil administered within the reconsolidation window
Trial: 35811050
Drug: Placebo oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oil administered within the reconsolidation window
Trial: 35811050
Drug: CBD-rich oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD-rich oil administered outside of the reconsolidation window
Trial: 33934618
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion at 1.25 IU/hour
Trial: 33934618
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion at 2.5 IU/hour
Trial: 33934618
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion at 5.0 IU/hour
Trial: 32109318
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid and hydroquinone 4% cream, sunscreen
Trial: 32109318
Drug: Hydroquinone 4%
RxNorm normalized name: HYDROQUINONE 4% CREAM
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroquinone 4% cream, sunscreen, and placebo capsules
Trial: 34560922
Drug: Olfactory ensheathing
RxNorm normalized name: BOS TAURUS OLFACTORY BULB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olfactory ensheathing cell therapy
Trial: 36056874
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg orally once daily for two weeks
Trial: 33272965
Drug: Ziltivekimab 2
RxNorm normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziltivekimab 2 mg
Trial: 33272965
Drug: Ziltivekimab 6
RxNorm normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziltivekimab 6 mg
Trial: 33272965
Drug: Ziltivekimab 20
RxNorm normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziltivekimab 20 mg
Trial: 33309466
Drug: Breathing Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breathing Therapy
Trial: 33942396
Drug: High-dose glucocorticoids,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose glucocorticoids, antibiotics, and monoclonal anti-TNFα antibody
Trial: 33942396
Drug: Anti-PD-1 antibodies
RxNorm normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 antibodies
Trial: 34001373
Drug: Unified Protocol
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A)
Trial: 35634479
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% (Group L)
Trial: 33196927
Drug: Psychoeducational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychoeducational intervention including psychoeducation on PND, coping skills, healthy mother/child interaction, and infant stimulation in addition to routine treatment.
Trial: 33196927
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving treatment as usual.
Trial: 35701334
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement therapy (TRT), transdermal gel (Tostran, 2%), maximum daily dose of 40 mg for 12 months
Trial: 34729060
Drug: Alendronate (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (70 mg for 12 weeks)
Trial: 36372869
Drug: LDL-C level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C level at 6 months after randomization set at a threshold of 70 mg/dl
Trial: 36372869
Drug: LDL-C level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C level below 70 mg/dl
Trial: 32617061
Drug: Oral macrolide
RxNorm normalized name: Macrobid Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral macrolide therapy
Trial: 32617061
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (oral steroid + macrolide)
Trial: 32617061
Drug: Control (Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Oral steroid group)
Trial: 33975465
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy (fluoropyrimidine and platinum-based agent)
Trial: 33975465
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chemotherapy (fluoropyrimidine and platinum-based agent)
Trial: 34463929
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (target serum level 3 mg/dl)
Trial: 34463929
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (placebo, target serum level 1.9 mg/dl)
Trial: 34463929
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate and normal saline (placebo)
Trial: 33343498
Drug: Sensorimotor therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensorimotor therapy
Trial: 32209071
Drug: Input quality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Input quality (availability of trained providers, drugs, and supplies)
Trial: 34649217
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day ALA
Trial: 34649217
Drug: 800 mg/day
RxNorm normalized name: RibaTab 800 mg/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg/day ALA
Trial: 34473896
Drug: Biological xenograft
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological xenograft
Trial: 36414304
Drug: Leucocyte-poor platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucocyte-poor platelet-rich plasma (PRP) injection after joint aspiration
Trial: 34559359
Drug: Ciprofol initial
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ciprofol initial infusion for 30 min followed by continuous maintenance infusion for 4 hours
Trial: 34559359
Drug: Ciprofol bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofol bolus dose followed by continuous maintenance infusion for 12 hours
Trial: 36644351
Drug: SCO-792 500
RxNorm normalized name: SCO-Spondin Derived Peptide NX210
DrugBank: NX-210c (DB18209)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCO-792 500 mg once daily (SCO-792 QD)
Trial: 36644351
Drug: SCO-792 500
RxNorm normalized name: SCO-Spondin Derived Peptide NX210
DrugBank: NX-210c (DB18209)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCO-792 500 mg 3 times daily (SCO-792 TID)
Trial: 33222542
Drug: Selective internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective internal radiation therapy (SIRT) with Y-90 resin microspheres
Trial: 36494706
Drug: Cardiac shockwave
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac shockwave therapy (SWT) during CABG surgery
Trial: 32473644
Drug: CABG surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CABG surgery with sham treatment
Trial: 32964809
Drug: PAI-indicated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAI-indicated treatment in STEPd study
Trial: 32964809
Drug: PAI-indicated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAI-indicated treatment in FreqMech study
Trial: 32964809
Drug: Cross-trial predictions
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cross-trial predictions for indicated treatment